Cardiac magnetic resonance assessment of right ventricular remodeling after anthracycline therapy

Autor(es):Mostrar menos -

de Souza, Thiago Ferreira ^[1] ; Silva, Thiago Quinaglia ^[1] ; Antunes-Correa, Ligia ^[1] ; Drobni, Zsofia D. ^[2] ; Costa, Felipe Osorio ^[1] ; Dertkigil, Sergio San Juan ^[1] ; Nadruz, Wilson ^[1] ; Brenelli, Facricio ^[1] ; Sposito, Andrei C. ^[1] ; Matos-Souza Jr, Jose Roberto ; Coelho, Otavio Rizzi ^[3] ; Neilan, Tomas G. ^[2] ; Jerosch-Herold, Michael ^{[4, 5]} ; Coelho-Filho, Otavio Rizzi ^[3]

Afiliação do(s) autor(es)

^[1] Univ Estadual Campinas, Div Cardiol, Dept Med, Fac Ciencias Med, UNICAMP, Rua Tessalia Viera Camargo 126, BR-13083887 Campinas, SP - Brazil

^[2] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02114 - USA

^[3] Matos-Souza Jr, Jr., Jose Roberto, Univ Estadual Campinas, Div Cardiol, Dept Med, Fac Ciencias Med, UNICAMP, Rua Tessalia Viera Camargo 126, BR-13083887 Campinas, SP - Brazil

^[4] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 - USA

^[5] Brigham & Womens Hosp, Noninvas Cardiovasc Imaging Program, 75 Francis St, Boston, MA 02115 - USA

• Tipo de documento: Artigo Científico
• Fonte: SCIENTIFIC REPORTS; v. 11, n. 1 AUG 24 2021.
• Citações Web of Science: 0

Resumo

There are limited data on the effects of anthracyclines on right ventricular (RV) structure, function, and tissue characteristics. The goal of this study was to investigate the effects of anthracyclines on the RV using cardiac magnetic resonance (CMR). This was a post-hoc analysis of a prospective study of 27 breast cancer (BC) patients (51.8 +/- 8.9 years) using CMR prior, and up to 3-times after anthracyclines (240 mg/m(2)) to measure RV volumes and mass, RV extracellular volume (ECV) and cardiomyocyte mass (CM). Before anthracyclines, LVEF (69.4 +/- 3.6%) and RVEF (55.6 +/- 9%) were normal. The median follow-up after anthracyclines was 399 days (IQR 310-517). The RVEF reached its nadir (46.3 +/- 6.8%) after 9-months (P < 0.001). RV mass-index and RV CM decreased to 13 +/- 2.8 g/m(2) and 8.13 +/- 2 g/m(2), respectively, at 16-months after anthracyclines. The RV ECV expanded from 0.26 +/- 0.07 by 0.14 (53%) to 0.40 +/- 0.1 (P < 0.001). The RV ECV expansion correlated with a decrease in RV mass-index (r = -0.46; P < 0.001) and the increase in CK-MB. An RV ESV index at baseline above its median predicted an increased risk of LV dysfunction post-anthracyclines. In BC patients treated with anthracyclines, RV atrophy, systolic dysfunction, and a parallel increase of diffuse interstitial fibrosis indicate a cardiotoxic response on a similar scale as previously seen in the systemic left ventricle. (AU)

• Processo FAPESP: 16/26209-1 - EMU concedido no processo 2015/15402-2: sistema de ergoespirometria
• Beneficiário: Otávio Rizzi Coelho-Filho
• Modalidade de apoio: Auxílio à Pesquisa - Programa Equipamentos Multiusuários
• Processo FAPESP: 15/15402-2 - Caracterização da fibrose intersticial e da hipertrofia dos cardiomiócitos pela ressonância magnética cardíaca: implicações no remodelamento precoce e na transição para insuficiência cardíaca
• Beneficiário: Otávio Rizzi Coelho-Filho
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores
• Processo FAPESP: 17/03708-5 - EMU concedido no processo 2015/15402-2: equipamento de ecocardiograma
• Beneficiário: Otávio Rizzi Coelho-Filho
• Modalidade de apoio: Auxílio à Pesquisa - Programa Equipamentos Multiusuários